Clinical Effect of Selective Serotonin Reuptake Inhibitors (SSRIs) on Fracture Healing

被引:2
|
作者
Mehta, Devan [1 ]
Ganta, Abhishek [1 ]
Bradaschia-Correa, Vivian [1 ]
Konda, Sanjit R. [1 ]
Egol, Kenneth A. [1 ]
Leucht, Philipp [1 ,2 ]
机构
[1] NYU Langone Orthoped Hosp, NYU Grossman Sch Med, Dept Orthoped Surg, New York, NY USA
[2] NYU Langone Orthoped Hosp, NYU Grossman Sch Med, 550 First Ave,Skirball 2-057, New York, NY 10016 USA
来源
关键词
BONE MASS; ANTIDEPRESSANTS;
D O I
10.1258/j.stain.258.123
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Purpose: Chronic use of selective serotonin reuptake inhibitors (SSRIs) for the treatment of depression has been linked to an imbalance in bone metabolism leading to osteoporosis. More recently, the use of SSRIs in murine models has been shown to delay bone healing both in vivo and in vitro by decreasing the osteoblastic differentiation and mineralization. The purpose of this study was to evaluate whether or not chronic use of SSRI's in nonunion patients increases their time to union after surgical intervention. Methods: We retrospectively analyzed 343 patients in a nonunion database to determine which patients were on SSRI medication. Of these patients, 139 could be contacted and of those 102 were not taking SSRIs and 37 were taking SSRIs. Patient's time to union from nonunion surgical intervention between each cohort at our institution was recorded as the primary outcome. Patient's medical comorbidities that could affect union rates such as diabetes and smoking status were also noted. Baseline Short Musculoskeletal Function Assess-ment (SMFA) index for bother and function were recorded from the time of nonunion surgery as well as last follow-up. Results: Compared to recent census data, we found sig-nificantly more patients in the nonunion cohort using SSRIs (26.6%) than patients in the general population using any type of antidepressant (11%). There was no significant dif-ference in the patients' baseline characteristics other than patients on SSRI treatment had a higher body mass index (BMI) and age (p = 0.048 and p = 0.043, respectively). There was no significant difference noted in the fracture types (p = 0.2063). Patients on SSRIs had a higher SMFA bother index and function index on follow-up (p = 0.0103, p = 0.0147). Patients in the SSRI group had a mean time to union from nonunion surgery of 6.1 months compared to 6.0 in patients without SSRI usage (p = 0.74). These did not reach statistical significance when subcohort analysis for long bone fractures was performed for the femur, tibia, and humerus. Conclusion: To our knowledge, this is the first clinical study to investigate the effects of SSRIs on fracture healing. While in vivo and in vitro murine models have shown that SSRIs can have a deleterious effect on osteoblastic activity, our retrospective analysis did not show a significant differ-ence in time to union between patients with chronic SSRI use and patients who have not been on SSRIs. However, this investigation did show a higher incidence of SSRI use in the nonunion cohort when compared to the general population. In the context of the recent animal model study, this may point to a negative effect of SSRI use on the acute fracture healing process.
引用
收藏
页码:260 / 264
页数:5
相关论文
共 50 条
  • [1] Serotonin Selective Reuptake Inhibitors (SSRIs) and Stroke
    Chollet, F.
    Rigal, J.
    Marque, P.
    Barbieux-Guillot, M.
    Raposo, N.
    Fabry, V.
    Albucher, J. F.
    Pariente, J.
    Loubinoux, I.
    CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2018, 18 (12)
  • [2] Selective serotonin reuptake inhibitors antidepressants (SSRIs)
    Chavez-Leon, Enrique
    Ontiveros Uribe, Martha Patricia
    Gomez, Carlos Serrano
    SALUD MENTAL, 2008, 31 (04) : 307 - 319
  • [3] Serotonin Selective Reuptake Inhibitors (SSRIs) and Stroke
    F. Chollet
    J. Rigal
    P. Marque
    M. Barbieux-Guillot
    N. Raposo
    V. Fabry
    J. F. Albucher
    J. Pariente
    I. Loubinoux
    Current Neurology and Neuroscience Reports, 2018, 18
  • [5] Selective Serotonin Reuptake Inhibitors (SSRIs) and Hyperprolactinemia
    Herlem, Emmanuelle
    Oger, Fany
    Germain, Marie Laure
    Trenque, Thierry
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2009, 18 : S85 - S85
  • [6] Selective Serotonin Reuptake Inhibitors (SSRIs) and Hyperprolactinemia
    Herlem, E.
    Oger, F.
    Germain, M. L.
    Trenque, T.
    DRUG SAFETY, 2009, 32 (10) : 958 - 958
  • [7] Selective Serotonin Reuptake Inhibitors (SSRIs) in Pregnancy: A Review
    Fleschler, Robin
    Peskin, Melissa. F.
    MCN-THE AMERICAN JOURNAL OF MATERNAL-CHILD NURSING, 2008, 33 (06) : 355 - 361
  • [8] Homotryptamines as potent and selective serotonin reuptake inhibitors (SSRIs)
    Schmitz, WD
    Denhart, DJ
    Brenner, AB
    Ditta, JL
    Mattson, RJ
    Mattson, GK
    Molski, TF
    Macor, JE
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (06) : 1619 - 1621
  • [9] Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery
    Legg, Lynn A.
    Tilney, Russel
    Hsieh, Cheng-Fang
    Wu, Simiao
    Lundstrom, Erik
    Rudberg, Ann-Sofie
    Kutlubaev, Mansur A.
    Dennis, Martin
    Barugh, Amanda
    Hackett, Maree L.
    Hankey, Graeme J.
    Mead, Gillian E.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (11):
  • [10] Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery
    Legg, Lynn A.
    Tilney, Russet
    Hsieh, Cheng-Fang
    Wu, Simiao
    Lundstrom, Erik
    Rudberg, Ann-Sofie
    Kutlubaev, Mansur A.
    Dennis, Martin
    Soleimani, Babak
    Barugh, Amanda
    Hackett, Maree L.
    Hankey, Graeme J.
    Mead, Gillian E.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2019, (11):